Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

Bausch Health

Status and phase

Completed

Phase 1

Conditions

Postoperative Complications

Constipation

Treatments

Drug: MOA-728

Study type

Interventional

Funder types

Industry

Identifiers

NCT00311350

3200A3-100

Details and patient eligibility

About

This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: